Konrad Hermann Stopsack

Reply to Johann S. de Bono, Maha Hussain, and Jinyu Kang's Letter to the Editor re: Konrad H. Stopsack. Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.09.024.

Stopsack KH.

Eur Urol. 2020 Dec 22. PMID: 33358233

Attenuation of SRC kinase activity augments PARP inhibitor-mediated synthetic lethality in BRCA2-altered prostate tumors.

Chakraborty G, Khan Patail N, Hirani R, Nandakumar S, Mazzu YZ, Yoshikawa Y, Atiq MO, Jehane L, Stopsack KH, Lee GM, Abida W, Morris MJ, Mucci LA, Danila DC, Kantoff PW.

Clin Cancer Res. 2020 Dec 17. PMID: 33334906

Cancer therapy shapes the fitness landscape of clonal hematopoiesis.

Bolton KL, Ptashkin RN, Gao T, Braunstein L, Devlin SM, Kelly D, Patel M, Berthon A, Syed A, Yabe M, Coombs CC, Caltabellotta NM, Walsh M, Offit K, Stadler Z, Mandelker D, Schulman J, Patel A, Philip J, Bernard E, Gundem G, Ossa JEA, Levine M, Martinez JSM, Farnoud N, Glodzik D, Li S, Robson ME, Lee C, Pharoah PDP, Stopsack KH, Spitzer B, Mantha S, Fagin J, Boucai L, Gibson CJ, Ebert BL, Young AL, Druley T, Takahashi K, Gillis N, Ball M, Padron E, Hyman DM, Baselga J, Norton L, Gardos S, Klimek VM, Scher H, Bajorin D, Paraiso E, Benayed R, Arcila ME, Ladanyi M, Solit DB, Berger MF, Tallman M, Garcia-Closas M, Chatterjee N, Diaz LA, Levine RL, Morton LM, Zehir A, Papaemmanuil E.

Nat Genet. 2020 11. 52(11):1219-1226. PMID: 33106634

Recommended definitions of aggressive prostate cancer for etiologic epidemiologic research.

Hurwitz LM, Agalliu I, Albanes D, Barry KH, Berndt SI, Cai Q, Chen C, Cheng I, Genkinger JM, Giles GG, Huang J, Joshu CE, Key TJ, Knutsen S, Koutros S, Langseth H, Li SX, MacInnis RJ, Markt SC, Penney KL, Perez-Cornago A, Rohan TE, Smith-Warner SA, Stampfer MJ, Stopsack KH, Tangen CM, Travis RC, Weinstein SJ, Wu L, Jacobs EJ, Mucci LA, Platz EA, Cook MB.

J Natl Cancer Inst. 2020 Oct 03. PMID: 33010161

Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib.

Stopsack KH.

Eur Urol. 2020 Oct 01. PMID: 33012578

Multiplex Immunofluorescence in Formalin-Fixed Paraffin-Embedded Tumor Tissue to Identify Single-Cell-Level PI3K Pathway Activation.

Stopsack KH, Huang Y, Tyekucheva S, Gerke TA, Bango C, Elfandy H, Bowden M, Penney KL, Roberts TM, Parmigiani G, Kantoff PW, Mucci LA, Loda M.

Clin Cancer Res. 2020 Nov 15. 26(22):5903-5913. PMID: 32913135

Inferences about drug safety in phase 3 trials in oncology: Examples from advanced prostate cancer.

Drago JZ, Gönen M, Thanarajasingam G, Sacks CA, Morris MJ, Kantoff PW, Stopsack KH.

J Natl Cancer Inst. 2020 Aug 28. PMID: 32857839

Tumor protein expression of the DNA repair gene BRCA1 and lethal prostate cancer.

Stopsack KH, Gerke T, Zareba P, Pettersson A, Chowdhury D, Ebot EM, Flavin R, Finn S, Kantoff PW, Stampfer MJ, Loda M, Fiorentino M, Mucci LA.

Carcinogenesis. 2020 Jul 14. 41(7):904-908. PMID: 32556091

Inferior Cancer Survival for Men with Localized High-grade Prostate Cancer but Low Prostate-specific Antigen.

Fankhauser CD, Penney KL, Gonzalez-Feliciano AG, Clarke NW, Hermanns T, Stopsack KH, Fiorentino M, Loda M, Mahal B, Gerke TA, Preston MA, Mucci LA.

Eur Urol. 2020 Oct. 78(4):637-639. PMID: 32624279

The association of diabetes with risk of prostate cancer defined by clinical and molecular features.

Feng X, Song M, Preston MA, Ma W, Hu Y, Pernar CH, Stopsack KH, Ebot EM, Fu BC, Zhang Y, Li N, Dai M, Liu L, Giovannucci EL, Mucci LA.

Br J Cancer. 2020 Aug. 123(4):657-665. PMID: 32467600